SCHEMBL881065

SCHEMBL881065

COc1ccc2c(c1)C=C(c1cc(C(F)(F)F)ccc1N1CCOCC1)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)O)cc21

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 4/20 0.40
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PRKCA P17252 1/20 0.37
MMP12 P39900 1/20 0.37
ERAP1 Q9NZ08 3/20 0.37
KCNH2 Q12809 5/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.36
ERAP2 Q6P179 1/20 0.35
CYP3A4 P08684 1/20 0.35
SCN5A Q14524 1/20 0.35
SCN9A Q15858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL880933 0.89 KCNH2 (0.49) NR1I2LMNASMN1; SMN2L3MBTL1KCNH2
SCHEMBL13520521 0.88 NR1I2 (0.39) NR1I2LMNAPRKCAMMP12KCNH2
SCHEMBL10186659 0.82 NR1I2 (0.42) NR1I2LMNASMN1; SMN2PRKCAMMP12
SCHEMBL10185755 0.82 PRKCA (0.44) NR1I2PRKCAMMP12KCNH2CYP3A4
SCHEMBL881073 0.81 NR1I2 (0.43) NR1I2LMNAPRKCAMMP12KCNH2
SCHEMBL841461 0.81 NR1I2 (0.49) NR1I2L3MBTL1PRKCAMMP12KCNH2
SCHEMBL881076 0.81 PRKCA (0.45) NR1I2PRKCAMMP12KCNH2CYP3A4
SCHEMBL880962 0.81 NR1I2 (0.46) NR1I2LMNASMN1; SMN2PRKCAMMP12
SCHEMBL13936872 0.80 NR1I2 (0.61) NR1I2L3MBTL1PRKCAMMP12KCNH2
SCHEMBL881001 0.79 NR1I2 (0.48) NR1I2L3MBTL1PRKCAMMP12KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2178878-B1 TETRACYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL MYERS SQUIBB CO (US) 2012-03-28 EP disclosed
WO-2009023487-A1 TETRACYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2009-02-19 WO disclosed